Earnings calendar

Regeneron Pharmaceuticals, Inc. (REGN) earnings: date, estimates, results and stock reactions

Next earnings: Q4 FY2026 on 2027-01-28 (expected, before the open). EPS estimate 25.80, revenue estimate 5.85B.

Over the last 12 reports the stock moved 6.2% on average (either way), rising 8 times and falling 4. EPS beat estimates 10 of 12 times; revenue 10 of 12. Close before the report date to the first close after it (two trading sessions, covering before-the-open and after-the-close reports).

QuarterReportedEPSEPS estimateEPS surpriseRevenueRevenue estimateStock move
Q3 FY20262026-10-3020.0716.51+21.6%5.12B4.58B+17.4%
Q2 FY20262026-07-3014.2910.16+40.6%4.29B3.82B+9.7%
Q1 FY20262026-04-299.478.91+6.3%3.61B3.48B-3.4%
Q4 FY20252026-01-3011.4410.74+6.5%3.88B3.81B+0.7%
Q3 FY20252025-10-2811.839.65+22.6%3.75B3.59B+11.5%
Q2 FY20252025-08-0112.898.43+52.9%3.68B3.29B+4.8%
Q1 FY20252025-04-298.228.62-4.6%3.03B3.25B-2.0%
Q4 FY20242025-02-0412.0711.21+7.7%3.79B3.74B+7.5%

REGN stock report · Earnings calendar